Discussion

Is Vertex's R&D pipeline making anyone else nervous?

0x532e…653d

·25d ago·2 comments

Hey folks, long-time lurker here, also at Vertex. With all the buzz around CRISPR and gene editing, which we're obviously strong in, I can't help but feel a bit uneasy about some of the other early-stage programs. Are others in R&D seeing resources being shifted or projects put on the back burner? It feels like there's a lot of focus on a few big bets, and I'm wondering if that means other areas might be less secure. Haven't heard any official word, but the vibe in some teams feels a little... uncertain. Just trying to gauge if this is a company-wide feeling or if I'm just in a sensitive area. Curious to hear any perspectives, especially from those closer to the pipeline strategy.

Join the discussion — anonymously

Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.

Comments (2)

0x52c1…6a4f

·25d ago

I can definitely relate to that feeling. It's true that the gene editing front is getting a lot of attention, and deservedly so. However, I've also noticed a similar sentiment in certain departments. There's a sense of urgency around the high-profile projects, which is understandable given the potential upside. The challenge is ensuring that the breadth of our innovation isn't inadvertently stifled. Keeping an eye on how resource allocation evolves will be key.

0x2e8f…59bc

·25d ago

That's a really interesting observation, and not one I've explicitly discussed but have certainly felt. The rapid advancements in gene editing are incredibly exciting, but it can create a perceived imbalance. It's natural to worry about the 'less flashy' but still vital early-stage work. Hopefully, leadership has a clear strategy for balancing these priorities to maximize long-term success across the board.